NextCure(NXTC) - 2025 Q4 - Annual Report

Financial Performance - The company reported significant losses, with no revenue generated from product sales, and anticipates continued losses for the foreseeable future[23] - The company has a history of significant losses and expects to continue incurring substantial losses for the foreseeable future, with no revenue generated from product sales to date[23] - There is substantial doubt regarding the company's ability to continue as a going concern, necessitating immediate additional funding[30] Financing Needs - The company requires substantial additional financing to pursue its business objectives, which may not be available on acceptable terms[23] - The company requires substantial additional financing to pursue its business objectives, which may not be available on acceptable terms[23] Regulatory Challenges - The regulatory approval processes for product candidates are lengthy and inherently unpredictable, impacting the timeline for commercialization[23] - Regulatory approval processes for product candidates are lengthy and inherently unpredictable, impacting the timeline for commercialization[23] - The company is studying product candidates in combination with other therapies, exposing it to additional regulatory risks[23] Clinical Trials - The company is currently developing product candidates SIM0505 and LNCB74, with ongoing preclinical studies and clinical trials[14] - There is a risk of difficulties in enrolling patients for clinical trials due to external factors such as pandemics[23] - The company has limited experience in designing and implementing clinical trials, which could lead to delays or increased costs[23] - The company has limited experience in designing and implementing clinical trials, which could result in delays or additional costs[23] Supply Chain and Competition - The company relies on third-party suppliers for key materials, and any disruption could adversely affect its operations[30] - The company relies on third-party suppliers for key materials, and any issues with these suppliers could harm its business[30] - The company faces significant competition from other biotechnology and pharmaceutical companies, impacting its market position[30] - The company faces significant competition from other biotechnology and pharmaceutical companies, which could affect its operating results[30] Personnel and Market Considerations - The company is highly dependent on key personnel, and failure to attract and retain qualified staff could hinder its business strategy[30] - The price of the company's common stock has been volatile and may fluctuate substantially in the future[30] - The company may need to establish marketing, sales, and distribution capabilities for any product candidates that receive regulatory approval to ensure successful commercialization[30]